Covidien sees strength in medical device unit as profits rise

The medical devices earnings news kept rolling in last week with Covidien ($COV) reporting good news with its medical device unit, which saw sales of $1.98 billion in the fiscal 2012 first quarter that ended in December, up 6% from $1.88 billion a year earlier. The company's results beat analyst expectations and sent its stock up, the Boston Business Journal reported. Covidien also saw profits of $494 million during the quarter, up from $427 million last year. Covidien release | More

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.